| Stereochemistry | ABSOLUTE |
| Molecular Formula | C31H55N3O6 |
| Molecular Weight | 565.7849 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCCCCCCCCCCCCCCCCCCCC(=O)NC1=NC(=O)N(C=C1)[C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O
InChI
InChIKey=SAMRUMKYXPVKPA-VFKOLLTISA-N
InChI=1S/C31H55N3O6/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-27(36)32-26-22-23-34(31(39)33-26)30-29(38)28(37)25(24-35)40-30/h22-23,25,28-30,35,37-38H,2-21,24H2,1H3,(H,32,33,36,39)/t25-,28-,29+,30-/m1/s1
Enocitabine is an anti-cancer nucleoside that was developed for the treatment of acute myeloid leukemia. Although the exact mechanism of its action is unknow, Enocitabine effectively inhibits tumor cell growht in vitro and the inhibition is supposed to be related to its metabolism to Ara-C, an inhibitor of DNA polymerase. The drug was approved in Japan and Korea and was marketed under the name Sunrabin, however, its current marketing status is unknown and is assumed to be discontinued.
Originator
Approval Year
Cmax
T1/2
PubMed
Patents
Sample Use Guides
T-cell depleted mononuclear cells from AML pa tients were exposed to Enocitabine at various doses (17.7, 35.3. or 70.7 uM) for 1, 6, or 24 h. Then the cell suspension was washed three times in alpha-MEM with 10% PCS, plated in methylcellulose culture, and incubated for another 7 days in the absence of the drug. Enocitabine suppressed primary and secondary blast colony formation in a dose responsive manner.
ACTIVE MOIETY
